Who is sponsoring GigAINt?

GigAINt is sponsored by Novartis Pharmaceuticals.

What condition does GigAINt study?

GigAINt studies Giant Cell Arteritis.

What drugs are being tested in GigAINt?

Interventions: Secukinumab 300 mg, s.c., Placebo to match Secukinumab, s.c..

What is the status of GigAINt?

GigAINt is currently COMPLETED.

Last reviewed 2026-02-27 · How we verify

Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remission (GigAINt)

NCT05380453 PHASE3 COMPLETED

The purpose of this study is to demonstrate the efficacy and safety of subcutaneously (s.c.) administered secukinumab 300 mg in combination with glucocorticoid taper regimen compared to placebo in combination with glucocorticoid taper regimen, in adult patients with new onset of giant cell arteritis (GCA) who are in clinical remission and who are eligible for treatment with glucocorticoid-monotherapy as per current clinical practice and treatment guidelines for the targeted participant population, thereby supporting health technology assessments (HTAs) of secukinumab in Germany.

Details

Lead sponsor	Novartis Pharmaceuticals
Phase	PHASE3
Status	COMPLETED
Enrolment	151
Start date	Thu Sep 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Feb 24 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Giant Cell Arteritis

Interventions

Secukinumab 300 mg, s.c.
Placebo to match Secukinumab, s.c.

Countries

Germany